thalidomide has been researched along with Granuloma, Hodgkin in 24 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| " This phase I/II study was conducted to determine the maximum tolerated dose (MTD), safety, and efficacy of lenalidomide combined with panobinostat in relapsed/refractory HL." | 2.84 | A Phase I/II Trial of Panobinostat in Combination With Lenalidomide in Patients With Relapsed or Refractory Hodgkin Lymphoma. ( Bartlett, NL; Blum, KA; Christian, BA; Devine, SM; Fehniger, TA; Jaglowski, SM; Maly, JJ; Phelps, MA; Sexton, JL; Wagner-Johnston, ND; Wei, L; Zhu, X, 2017) |
| "Lenalidomide was administered at 20 mg/day for 21 days and cyclophosphamide at 50 mg/day for 28 days (cycles every 28 days)." | 2.80 | A phase II study to evaluate lenalidomide in combination with metronomic-dose cyclophosphamide in patients with heavily pretreated classical Hodgkin lymphoma. ( Casanova, M; García-Sanz, R; Labrador, J; Pastor, M; Provencio, M; Quero-Blanco, C; Rueda, A; Salar, A, 2015) |
| "Patients with Hodgkin's Lymphoma (HL) who relapse or progress after primary therapy and subsequent high dose chemotherapy with autologous stem cell transplantation (ASCT) cannot be cured with conventional treatment." | 2.72 | A phase II study of thalidomide and vinblastine for palliative patients with Hodgkin's lymphoma. ( Crump, M; Keating, A; Kuruvilla, J; McCrae, J; Mollee, P; Nagy, T; Panzarella, T; Song, K, 2006) |
| "Most patients with Hodgkin lymphoma (HL) are cured with modern combined modality first-line treatments." | 2.50 | An update on emerging drugs for Hodgkin lymphoma. ( Diehl, V; von Tresckow, B, 2014) |
| "Primary treatment for classic Hodgkin lymphoma (HL) remains highly effective with chemotherapy alone or combined-modality therapy." | 2.46 | Gemcitabine and other new cytotoxic drugs: will any find their way into primary therapy? ( Dougherty, DW; Friedberg, JW, 2010) |
| "Approximately 80% of Hodgkin's lymphoma (HL) patients achieve long-term remission after primary chemotherapy or chemo/radiotherapy." | 2.44 | Hodgkin's lymphoma: current treatment strategies and novel approaches. ( Borchmann, P; Eichenauer, DA; Engert, A; Fuchs, M, 2008) |
| "Lenalidomide (25 mg daily) treatment was then initiated in a continuous dosing schedule." | 1.36 | Lenalidomide induced good clinical response in a patient with multiple relapsed and refractory Hodgkin's lymphoma. ( Kolonic, SO; Mandac, I, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (4.17) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (12.50) | 29.6817 |
| 2010's | 20 (83.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Maly, JJ | 1 |
| Christian, BA | 1 |
| Zhu, X | 1 |
| Wei, L | 1 |
| Sexton, JL | 1 |
| Jaglowski, SM | 1 |
| Devine, SM | 1 |
| Fehniger, TA | 2 |
| Wagner-Johnston, ND | 2 |
| Phelps, MA | 1 |
| Bartlett, NL | 2 |
| Blum, KA | 2 |
| Zago, M | 1 |
| Adam, P | 1 |
| Goldschmidt, H | 1 |
| Fend, F | 1 |
| Kanz, L | 1 |
| Weisel, K | 1 |
| von Tresckow, B | 1 |
| Diehl, V | 1 |
| Pellegrini, C | 1 |
| Maglie, R | 1 |
| Argnani, L | 1 |
| Pileri, S | 1 |
| Zinzani, PL | 1 |
| Rueda, A | 1 |
| García-Sanz, R | 2 |
| Pastor, M | 1 |
| Salar, A | 2 |
| Labrador, J | 1 |
| Quero-Blanco, C | 1 |
| Casanova, M | 1 |
| Provencio, M | 1 |
| Printz, C | 1 |
| Cheah, CY | 1 |
| Mistry, HE | 1 |
| Konoplev, S | 1 |
| Fowler, NH | 1 |
| Rammaert, B | 1 |
| Candon, S | 1 |
| Maunoury, C | 1 |
| Bougnoux, ME | 1 |
| Jouvion, G | 1 |
| Braun, T | 1 |
| Correas, JM | 1 |
| Lortholary, O | 1 |
| Böll, B | 1 |
| Borchmann, P | 2 |
| Topp, MS | 1 |
| Hänel, M | 1 |
| Reiners, KS | 1 |
| Engert, A | 2 |
| Naumann, R | 1 |
| González-López, TJ | 1 |
| Vázquez, L | 1 |
| Hermida, G | 1 |
| Graciani, IF | 1 |
| San Miguel, JF | 1 |
| Corazzelli, G | 1 |
| De Filippi, R | 1 |
| Capobianco, G | 1 |
| Frigeri, F | 1 |
| De Rosa, V | 1 |
| Iaccarino, G | 1 |
| Russo, F | 1 |
| Arcamone, M | 1 |
| Becchimanzi, C | 1 |
| Crisci, S | 1 |
| Marcacci, G | 1 |
| Amoroso, B | 1 |
| Lastoria, S | 1 |
| Pinto, A | 1 |
| Gonçalves, F | 1 |
| Dougherty, DW | 1 |
| Friedberg, JW | 1 |
| Mandac, I | 1 |
| Kolonic, SO | 1 |
| Tempescul, A | 1 |
| Ianotto, JC | 1 |
| Eveillard, JR | 1 |
| Guillerm, G | 1 |
| Berthou, C | 1 |
| Eichenauer, DA | 1 |
| Fuchs, M | 1 |
| Larson, S | 1 |
| Trinkaus, K | 1 |
| Siegel, MJ | 1 |
| Cashen, AF | 1 |
| Fenske, TS | 1 |
| Hurd, DD | 1 |
| Goy, A | 1 |
| Schneider, SE | 1 |
| Keppel, CR | 1 |
| Carson, KR | 1 |
| Ramchandren, R | 1 |
| Moskowitz, AJ | 1 |
| Chim, CS | 1 |
| Choi, PT | 1 |
| Lee, WK | 1 |
| Curto Barredo, L | 1 |
| Pujol, RM | 1 |
| Garcia, M | 1 |
| Gallardo, F | 1 |
| Kuruvilla, J | 1 |
| Song, K | 1 |
| Mollee, P | 1 |
| Panzarella, T | 1 |
| McCrae, J | 1 |
| Nagy, T | 1 |
| Crump, M | 1 |
| Keating, A | 1 |
| D'Orazio, AI | 1 |
| Roe, FJ | 1 |
| Walters, MA | 1 |
| Mitchley, BC | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase II Trial of Panobinostat and Lenalidomide in Patients With Relapsed or Refractory Hodgkin's Lymphoma[NCT01460940] | Phase 2 | 24 participants (Actual) | Interventional | 2011-10-13 | Completed | ||
| A Pilot Study of Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplantation in Patients With Relapsed/Refractory Hodgkin Lymphoma[NCT01207921] | Phase 1 | 28 participants (Actual) | Interventional | 2011-04-28 | Completed | ||
| A Phase II Multicenter Study of Lenalidomide in Relapsed or Refractory Classical Hodgkin Lymphoma[NCT00540007] | Phase 2 | 80 participants (Actual) | Interventional | 2007-09-06 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Overall response rate (CR + PR) will be determined using the International response criteria with combined panobinostat and lenalidomide in patients with relapsed or refractory Hodgkin's lymphoma. (NCT01460940)
Timeframe: up to 24 months
| Intervention | percentage of patients (Number) |
|---|---|
| Lenalidomide and Panobinostat | 16.7 |
Determined from the date of start of therapy to death from any cause or censored at the last date the patient is known to be alive (NCT01460940)
Timeframe: 3-5 years
| Intervention | months (Median) |
|---|---|
| Lenalidomide and Panobinostat | 3.8 |
Safety and tolerability will be assessed for patients using the NIH-NCI Common Terminology Criteria (CTCAE) version 4.0 (NCT01460940)
Timeframe: up to 24 months
| Intervention | percentage of patients (Number) | |||
|---|---|---|---|---|
| neutropenia | thrombocytopenia | febrile neutropenia | hypophosphatemia | |
| Lenalidomide and Panobinostat | 58.3 | 41.7 | 25.0 | 25.0 |
"Cytostatic overall response rate = CR + PR + SD greater than or equal to 6 months~Definitions per 2007 Cheson Lymphoma Response Criteria" (NCT00540007)
Timeframe: From 6 months through 3.5 years after study entry
| Intervention | Participants (Count of Participants) |
|---|---|
| Cohort 1 - Lenalidomide Daily on Days 1-21 | 15 |
| Cohort 2 - Lenalidomide Daily on Days 1-28 | 18 |
-Duration of response: defined as the interval from the date of response (CR or PR) is documented to the date of progression, taking as reference the smallest measurements recorded since the treatment started (NCT00540007)
Timeframe: Through 3.5 years from study entry or until disease progression
| Intervention | months (Median) |
|---|---|
| Cohort 1 - Lenalidomide Daily on Days 1-21 | 3.68 |
| Cohort 2 - Lenalidomide Daily on Days 1-28 | 4.08 |
-Event-free survival (time to treatment failure) is measured from the time from study entry to any treatment failure including disease progression, or discontinuation of treatment for any reason (eg, disease progression, toxicity, patient preference, initiation of new treatment without documented progression, or death). (NCT00540007)
Timeframe: Through 3.5 years from study entry or until disease progression
| Intervention | months (Median) |
|---|---|
| Cohort 1 - Lenalidomide Daily on Days 1-21 | 3.78 |
| Cohort 2 - Lenalidomide Daily on Days 1-28 | 3.93 |
"Overall response rate = CR + PR~Definitions per 2007 Cheson Lymphoma Response Criteria" (NCT00540007)
Timeframe: Through 3.5 years from study entry or until disease progression
| Intervention | percentage of participants (Number) |
|---|---|
| Cohort 1 - Lenalidomide Daily on Days 1-21 | 21.0 |
| Cohort 2 - Lenalidomide Daily on Days 1-28 | 28.6 |
Overall survival is defined as the time from entry onto the clinical trial until death as a result of any cause. (NCT00540007)
Timeframe: Through 3.5 years from study entry or until disease progression
| Intervention | months (Median) |
|---|---|
| Cohort 1 - Lenalidomide Daily on Days 1-21 | 17.434 |
| Cohort 2 - Lenalidomide Daily on Days 1-28 | 23.717 |
(NCT00540007)
Timeframe: Through 3.5 years from study entry or until disease progression
| Intervention | months (Median) |
|---|---|
| Cohort 1 - Lenalidomide Daily on Days 1-21 | 3.78 |
| Cohort 2 - Lenalidomide Daily on Days 1-28 | 3.93 |
-Time to progression (TTP) is defined as the time from study entry until documented lymphoma progression or death as a result of lymphoma. (NCT00540007)
Timeframe: Through 3.5 years from study entry or until disease progression
| Intervention | months (Median) |
|---|---|
| Cohort 1 - Lenalidomide Daily on Days 1-21 | 3.68 |
| Cohort 2 | 4.08 |
"Adverse events were graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 3.0~The higher the grade the worse the adverse event was considered" (NCT00540007)
Timeframe: 30 days following the completion of treatment
| Intervention | participants (Number) | |||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Neutropenia | Leukopenia | Anemia | Lymphopenia | Thrombocytopenia | Fatigue | AST | ALT | Bilirubin | Sensory neuropathy | Dehydration | Infection without neutropenia | Infection with neutropenia | Edema | Dyspnea | Pleural effusion | Alkaline phosphatase | Abdominal pain | Low potassium | Low sodium | Low albumin | Low calcium | High calcium | Low phosphorus | Hearing loss | Thrombosis/embolism | Rash | Febrile neutropenia | Pneumonia | High potassium | Hyperuricemia | Confusion | Dizziness | Speech impairment | Chest pain | Extremity pain | Muscle pain | Secondary malignancy - MDS | |
| Cohort 1 - Lenalidomide Daily on Days 1-21 | 18 | 11 | 10 | 9 | 7 | 3 | 3 | 2 | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 2 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cohort 2 | 20 | 13 | 4 | 10 | 8 | 2 | 1 | 1 | 2 | 0 | 0 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 2 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 1 | 2 | 1 | 1 |
5 reviews available for thalidomide and Granuloma, Hodgkin
| Article | Year |
|---|---|
An update on emerging drugs for Hodgkin lymphoma.
Topics: Brentuximab Vedotin; Histone Deacetylase Inhibitors; Hodgkin Disease; Humans; Immunoconjugates; Janu | 2014 |
Gemcitabine and other new cytotoxic drugs: will any find their way into primary therapy?
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Bendamustine | 2010 |
Hodgkin's lymphoma: current treatment strategies and novel approaches.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Clinical Trials as Topic; Hematopoietic Stem Cell Tra | 2008 |
Advances in the treatment of relapsed or refractory Hodgkin's lymphoma.
Topics: Antibodies, Monoclonal, Murine-Derived; Boronic Acids; Bortezomib; Brentuximab Vedotin; Drug Therapy | 2012 |
Novel agents in Hodgkin lymphoma.
Topics: Antineoplastic Agents; Bendamustine Hydrochloride; Brentuximab Vedotin; Everolimus; Histone Deacetyl | 2012 |
5 trials available for thalidomide and Granuloma, Hodgkin
| Article | Year |
|---|---|
A Phase I/II Trial of Panobinostat in Combination With Lenalidomide in Patients With Relapsed or Refractory Hodgkin Lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Hodgkin Disease; Humans; Hydrox | 2017 |
A phase II study to evaluate lenalidomide in combination with metronomic-dose cyclophosphamide in patients with heavily pretreated classical Hodgkin lymphoma.
Topics: Administration, Metronomic; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; | 2015 |
Lenalidomide in patients with refractory or multiple relapsed Hodgkin lymphoma.
Topics: Adult; Antineoplastic Agents; Female; Hodgkin Disease; Humans; Lenalidomide; Male; Middle Aged; Neop | 2010 |
A phase 2 multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma.
Topics: Adult; Antineoplastic Agents; Cell Line, Tumor; Chemokine CCL17; Chemokine CCL22; Disease-Free Survi | 2011 |
A phase II study of thalidomide and vinblastine for palliative patients with Hodgkin's lymphoma.
Topics: Administration, Oral; Adult; Antineoplastic Combined Chemotherapy Protocols; Female; Hodgkin Disease | 2006 |
14 other studies available for thalidomide and Granuloma, Hodgkin
| Article | Year |
|---|---|
Classical hodgkin lymphoma as de novo B-cell malignancy after treatment of multiple myeloma in the pre-lenalidomide era.
Topics: B-Lymphocytes; Female; Hodgkin Disease; Humans; Immunologic Factors; Lenalidomide; Middle Aged; Mult | 2014 |
Impressive response to pegylated liposomal doxorubicin after allogeneic transplantation in a multi-relapsed Hodgkin's lymphoma.
Topics: Allografts; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bendamustin | 2016 |
New treatments highlighted for lymphoma and multiple myeloma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brentuximab Vedotin; Chemothe | 2015 |
Complete remission following lenalidomide and rituximab in a patient with heavily pretreated nodular lymphocyte predominant Hodgkin lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Female; Hodgkin Disease; Humans; Lenalidomide | 2016 |
Thalidomide for steroid-dependent chronic disseminated candidiasis after stem cell transplantation: A case report.
Topics: Antifungal Agents; Bone Marrow Transplantation; Candida albicans; Candidiasis; Chronic Disease; Fluc | 2017 |
The combination of thalidomide, cyclophosphamide and dexamethasone is potentially useful in highly resistant Hodgkin's lymphoma.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemo | 2010 |
Tumor flare reactions and response to lenalidomide in patients with refractory classic Hodgkin lymphoma.
Topics: Adult; Anti-Inflammatory Agents; Antineoplastic Agents; Compassionate Use Trials; Hodgkin Disease; H | 2010 |
Thalidomide for the control of severe paraneoplastic pruritus associated with Hodgkin's disease.
Topics: Antineoplastic Combined Chemotherapy Protocols; Fatal Outcome; Female; Hodgkin Disease; Humans; Immu | 2010 |
Lenalidomide induced good clinical response in a patient with multiple relapsed and refractory Hodgkin's lymphoma.
Topics: Adult; Antineoplastic Agents; Drug Resistance, Neoplasm; Female; Hodgkin Disease; Humans; Lenalidomi | 2010 |
ESHAP chemotherapy regimen associated to lenalidomide induces complete isotopic remission in Hodgkin's lymphoma relapsing after autologous stem cell transplantation.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cytarabine; Etoposide; Hematopoiet | 2011 |
Hodgkin's lymphoma as a second cancer in multiple myeloma never exposed to lenalidomide.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Boronic Acids; Bortezomib; Combined Modal | 2013 |
Lenalidomide-induced paronychia.
Topics: Adult; Angiogenesis Inhibitors; Female; Hodgkin Disease; Humans; Lenalidomide; Paronychia; Thalidomi | 2013 |
37th Annual American Society of Clinical Oncology Meeting. San Francisco, CA. May 12-15, 2001.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD; Antigens, Differentiat | 2001 |
Tumour-incidence in progeny of thalidomide-treated mice.
Topics: Abnormalities, Drug-Induced; Animals; Animals, Newborn; Carcinoma, Hepatocellular; Female; Hodgkin D | 1967 |